Business
Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure 100% of this responder group had clinically meaningful pain relief at 4-6 weeks post-procedure Trial remains on track to complete enrollment by year-end 2024 THE WOODLANDS, TX, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced 4-6 week preliminary positive results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial (the “Trial”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. “We are encouraged by the significant, sustained pain reduction demonstrated from the lead-in patients in our ongoing first-in-human trial. These are very sick individuals, who up until this point primarily relied on opioids to help mitigate their pain, which our baseline data shows were not effective. Following our treatment, all the responders had a clinically meaningful mean reduction in pain from 8 to 1.33 on the VAS pain scale at 4-6 weeks post-procedure,” commented Brad Hauser, Chief Executive Officer of Autonomix. “While these data are preliminary, we are excited about our precision nerve-targeted technology and the potential it has to revolutionize electrophysiology therapies.” Summary of Topline Results 4-6 Weeks Post-Procedure As previously announced, three patients were treated with femoral access and two were treated with brachial access. All patients treated with femoral access positively responded to treatment and patients treated with brachial access showed no improvement in their pain scores. The results presented in the charts above are for the three patients in the responder group.60% of patients responded with a mean of 6.67, or 83%, reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure.66% of responders reported a VAS pain score of 0 or 1 with a greater than 7-point reduction in pain score at 4-6 w...